DEC 30, 2016 2:11 PM PST

New Findings Drive Home Cancer's Vast Genetic Diversity

WRITTEN BY: Xuan Pham

A common misconception is that cancer is caused by a single mutation in the genetic code. In many cases, however, the single mutation is just the beginning of a cascade of genetic changes that snowball out of control. The complexity of these changes are highlighted in the most recent study of cancer, showing that just one type of cancer contains over 2,000 different variations alone.

Image credit: Pixabay.com

"A tumor is not a single disease," said Dechen Lin, assistant professor and research scientist in the Division of Hematology and Oncology in the Cedars-Sinai Department of Medicine, and the study’s co-author. "It's many diseases within the same person and over time. There are millions of cells in a tumor, and a significant proportion of them are different from each other."

In particular, cancer has been described as a process of clonal expansion by Bert Vogelstein, a leading cancer geneticist from Johns Hopkins. Essentially, mutations begets more mutations as cancer continues to divide and proliferate. So, by the time the cancer becomes advanced, the original mutation is now just one in a sea of other mutations.

But while cancer biologists new cells from a single tumor sample could be wildly different, they didn’t know the degree to which the differences can occur.

To study cancer’s heterogeneity, researchers from the Cedars-Sinai Medical Center focused on esophageal squamous cell carcinoma - cancer that occurs along the pipe that connects the throat and the stomach. With 51 samples from 13 patients, the team catalogued the variety of mutations that they found. They included mutations at the DNA level, as well as mutations at the epigenetic level.

In total, the team found a whopping 2,178 different genetic variations. This number is staggering considering the small number of patients and samples sizes that they started with. The vast number of changes underscores the deep complexities within cancer that we are only beginning to unravel.

"This study is on the leading edge of looking within a tumor for heterogeneity, or variations, across patients and within the same patient. It also is one of the very first studies to look at epigenetic changes from different areas within a single tumor in a global way," said Benjamin Berman, the study's co-senior author.

Considering the vast genetic diversity within the tumor and within any person, it’s a wonder that any drug works as expected. But in the case of treating cancer, the complexities of a single cancer type can explain why so many drugs do fail. In particular, drugs that target a particular pathway or mutation can very easily be thwarted by the thousands of other mutations at play within a cancer environment.

"Evidence suggests that tumor heterogeneity is one of the major causes of drug resistance and treatment failure in cancer," said H. Phillip Koeffler, professor of Medicine and the Mark Goodson Chair in Oncology Research at Cedars-Sinai, and the study’s co-senior author. "In light of this situation, deciphering the genomic diversity and evolution of tumors can provide a basis for identifying new targets and designing personalized medicine strategies."

Additional source: Cedars-Sinai Medical Center.

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 12, 2021
Cancer
Using astronomy to image cancer tumors
JUN 12, 2021
Using astronomy to image cancer tumors
In an interdisciplinary breakthrough, a recent study published in Science describes the development of a new platform, d ...
JUN 27, 2021
Cancer
Are e-cigarettes actually helpful for smoking cessation?
JUN 27, 2021
Are e-cigarettes actually helpful for smoking cessation?
New research published in The Lancet Public Health reports on a study that looked at interventions targeting e-cigarette ...
JUL 08, 2021
Cancer
Activating p53 May Boost Efficacy of Cancer Immunotherapy
JUL 08, 2021
Activating p53 May Boost Efficacy of Cancer Immunotherapy
Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These ...
SEP 16, 2021
Cancer
Inspiring Hope during Childhood Cancer Awareness Month
SEP 16, 2021
Inspiring Hope during Childhood Cancer Awareness Month
Childhood cancers, also known as pediatric cancers, are diagnosed in patients up to 14 years old.  Estimates for 20 ...
SEP 23, 2021
Drug Discovery & Development
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
SEP 23, 2021
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to ...
OCT 04, 2021
Cancer
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
OCT 04, 2021
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
Reports indicate that caffeine consumption in the United States is greatest in adults aged 50 – 64.  Coincide ...
Loading Comments...